New Treatments & Clinical Trials for Chronic Myeloid Leukemia

Chronic myeloid leukemia is a blood cancer driven by a gene mutation that produces an abnormal protein called BCR-ABL. Tyrosine kinase inhibitors — pills that block this protein — have transformed CML from a fatal disease into one most people live with long-term. Current research focuses on stopping treatment safely, overcoming resistance, and eliminating residual cancer cells.

What's actually going on in research

Trials are testing newer tyrosine kinase inhibitors with fewer side effects, strategies for treatment-free remission after years on therapy, and drugs that target resistant mutations. Researchers are also studying combination approaches that might eliminate leukemia cells that persist despite treatment, and predictive markers that identify who can safely stop medication.

What to know before you search

Eligibility typically depends on disease phase (chronic, accelerated, or blast), previous tyrosine kinase inhibitor treatments, response level, and specific mutations if resistance has developed.

What types of trials are currently open

• First-line treatment trials — Comparing newer tyrosine kinase inhibitors to imatinib in newly diagnosed CML to see which achieves deeper remission faster.
• Resistance trials — Testing drugs for people whose CML no longer responds to their current tyrosine kinase inhibitor, often due to additional mutations.
• Treatment discontinuation trials — Carefully monitored studies where people in deep remission stop their medication to see if remission holds without treatment.
• Combination therapy trials — Adding a second drug to a tyrosine kinase inhibitor to try to eliminate residual leukemia cells and increase cure rates.
• Quality of life studies — Tracking side effects, fatigue, and daily functioning on different CML treatments to understand long-term tolerability.